• Leading cardiologist says bisantrene has potential to significantly change cancer treatment landscape
• Bisantrene could minimise damage to the heart linked to many cancer therapies
• New CEO is prioritising swift delivery of bisantrene to patients and maximising shareholder returns

For all the excitement about curing cancer or the disease going into remission, the relief for some patients can often be short-lived if the treatment leaves them with other potentially long-term health repercussions.

Cardiovascular health problems are typically the most common, but Race Oncology (ASX:RAC) is working to minimise damage to the heart linked to almost all cancer therapies with its core asset bisantrene. Read more here.